ArticleCurrent opinion in psychiatry2005
Pharmacogenetics in mood disorder.
Article in Current opinion in psychiatry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- Observational
- Association between polymorphism of the norepinephrine transporter gene rs2242446 and rs5669 loci and depression disorders.International journal of clinical and experimental medicine · 2015Article
- Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.Current psychiatry reports · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewNot all patients with mood disorder respond well to drug treatment. Emerging data suggest that genetic mechanisms could be involved. We searched the literature database and highlighted recent molecular genetic studies pertaining to drug response in mood disorders. RECENT
findingsRecent pharmacogenetic studies in mood disorders have reported generally positive findings supporting the view that genotyping may improve the confidence of prospectively identifying treatment response and adverse outcomes. SUMMARY: The evidence documenting genotype-based response to drug treatment is rapidly expanding. Genes encoding target receptors and signal transduction systems may predict the efficacy of drug therapy in mood disorders. Additional predictors of treatment response in bipolar disorder may include the immediate early genes, mitochondrial genes and epigenetic mechanisms, although some of these studies are still preliminary.
Identifiers
16639181PMC2268900W90497428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.